Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo Ships Guaifenesin/PSE Tablets, But Single-Ingredient Snags Linger

This article was originally published in The Tan Sheet

Executive Summary

Perrigo launches store brand Mucinex D, containing guaifenesin and PSE, manufactured by Allergan, but also suspends marketing its own guaifenesin product due to problems with an excipient used in the formula.

You may also be interested in...



Perrigo Gains US Approval For OTC Guaifenesin/Pseudoephedrine Manufacturing

Predominant US OTC private label/store brand provider plans commercialize products in second half. Firm has yet to set date to release 2021 full-year and fourth-quarter results.

Perrigo Glows From Mucinex Private Label Plan, Starboard Plug

Perrigo plans to introduce two more Mucinex store brand products within six months after a series of manufacturing stumbles, CEO John Hendrickson says. The firm's private label prowess, says activist investor Jeffrey Smith, is insurance that it will grow as e-commerce grows.

Perrigo Glows From Mucinex Private Label Plan, Starboard Plug

Perrigo plans to introduce two more Mucinex store brand products within six months after a series of manufacturing stumbles, CEO John Hendrickson says. The firm's private label prowess, says activist investor Jeffrey Smith, is insurance that it will grow as e-commerce grows.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS108112

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel